Phase 2 Study of Gemcitabine Chemoablation for Treating Low-Grade Bladder Cancer
Single Arm, Open-Label Trial Evaluating Safety and Effectiveness
Led by Ekaterina Laukhtina · Updated on 2025-06-13
47
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of intravesical chemoablation with gemcitabine in patients who have low-grade bladder cancer confirmed by biopsy. This open-label Phase 2 clinical trial aims to assess the treatments effectiveness, safety, and tolerability in this patient group. The study focuses on patients with recurrent or primary Ta low-grade bladder cancer who meet specific tumor size and lesion number limits.
Participants will receive six weekly instillations of gemcitabine directly into the bladder. This treatment approach is designed to treat the bladder cancer locally without surgery. The study includes a single treatment arm with no placebo or comparator group. The treatment period will be followed by monitoring to evaluate responses and side effects.
Throughout the study, patients will undergo cystoscopy and bladder examinations, including photo documentation of tumors, to assess clinical and pathological responses at the end of treatment and during follow-up visits at 1 and 3 months post-treatment. Patient-reported outcomes on quality of life and symptoms will be collected weekly during treatment and at follow-up visits. Researchers will monitor participants for safety and treatment effects during these visits, with the total study duration spanning several months.
CONDITIONS
Brief Title
Chemoablation for Low-Grade Bladder Cancer
Research Team
E
Ekaterina Laukhtina Dr., Medical Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male or female participants aged 18 years or older who provide informed consent
Diagnosis of recurrent or primary Ta low-grade bladder cancer confirmed by biopsy within 8 weeks before screening
Largest tumor lesion diameter is 15 mm or less
Five or fewer bladder tumor lesions present
Cystoscopy with bladder diagram and photo documentation of tumors
Recurrence of non-muscle invasive bladder cancer (low or intermediate risk)
Requires treatment with transurethral resection of bladder tumors (TURBT)
Negative voiding cytology for high-grade disease within 8 weeks before screening
No lymph node or distant metastasis
Use of effective contraception during study and for 6 months after treatment for males and females
Negative pregnancy test within 2 weeks prior to enrollment for females of childbearing potential
Willing and able to provide informed consent
You will not qualify if you...
Tumors suspected to be high-grade by clinicians
Positive high-grade cytology according to Paris criteria
Tumor diameter greater than 15 mm
More than five bladder tumor lesions
Any previous intravesical therapy within 1 year
Previous high-grade non-muscle invasive bladder cancer within last 3 years
Past or current muscle invasive or metastatic bladder cancer
History of upper tract urothelial carcinoma
Clinically significant urethral stricture preventing catheter use
History of neurogenic bladder or active urinary retention
Active urinary tract infection not resolved before treatment
Refusal to participate in the study
Known positive HIV test
Pregnant or breastfeeding females
Females of childbearing potential not using adequate contraception
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 weeks
Participants receive six weekly intravesical instillations of gemcitabine to treat low-grade bladder cancer.
Weekly visits for 6 weeks
Follow-up
Duration - 3 months
Participants are monitored for treatment response and safety with visits at 1 and 3 months post-treatment.
2 visits (in-person) at 1 and 3 months post-treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Phase 1 Study Evaluating Safety and Pharmacokinetics of Intravesical UGN-501 in Adults with Recurrent Non-Muscle Invasive Bladder Cancer
Predicting Recurrence and Progression Risk After Bladder Tumor Surgery Using Intraoperative Fluid Absorption and Blood DNA Changes
Evaluation of T-bren Versus Platinum-Based Chemotherapy for HER2-Expressing Metastatic Urothelial Cancer After Anti-PD-L1 Therapy Progression
Phase 2 Study of Gemcitabine Chemoablation for Treating Low-Grade Bladder Cancer
Single Arm, Open-Label Trial Evaluating Safety and Effectiveness
Study of Vitamin B3 with Tislelizumab, Gemcitabine, and Cisplatin for Bladder Cancer Patients
Evaluating Safety and Effects Following Antibiotic Use
Virtual Exercise Program to Maintain Function and Prevent Disability in Cancer Patients Undergoing Chemotherapy
Phase 3 Study of Disitamab Vedotin Combined with BCG Versus BCG Alone in Adults with HER2-Positive, High-Risk Non-Muscle-Invasive Bladder Cancer
Personalized 6-Month Program to Reduce Frailty in Older Adults Undergoing Surgery for Bladder or Kidney Cancer
Phase 3 Randomized Trial Comparing Intravesical TARA-002 to Chemotherapy in Adults With BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
Randomized Study Comparing Active Surveillance to Continued Systemic Immunotherapy After Tumor-Free Status in Extensive Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Massimo Maffezzini, Fabio Campodonico, Giorgio Canepa...
Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.